May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Verteporfin in Combination With Intravitreal Triamcinolone for CNV Due to AMD
Author Affiliations & Notes
  • A.J. Augustin
    Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany
  • I. Offermann
    Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany
  • U. Schmidt–Erfurth
    Department of Ophthalmology, University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships  A.J. Augustin, Novartis C, R; I. Offermann, Novartis C, R; U. Schmidt–Erfurth, Novartis C, P, R.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3567. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.J. Augustin, I. Offermann, U. Schmidt–Erfurth; Verteporfin in Combination With Intravitreal Triamcinolone for CNV Due to AMD . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3567.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To report the findings of patients treated with verteporfin PDT combined with intravitreal triamcinolone for CNV associated with AMD. Methods: One hundred and ninetynine patients presenting with CNV due to AMD were included in this prospective, noncomparative, interventional case series. The diagnosis and active leakage were confirmed by fluorescein angiography (FA). Purified TA was administered by intravitreal injection 16 hours after verteporfin therapy. Assessments included visual acuity testing, fundus and slit–lamp examination, tonometry and FA. Results: The mean age of the patients was 75.4 years and 80.4% of patients presented with subfoveal lesions, 10.1% with juxtafoveal lesions, and 9.5% with extrafoveal lesions. The mean follow–up was 30.5 weeks (up to 119 weeks).Baseline visual acuity ranged from hand movement to 20/100 with a mean of 20/125. An improvement of visual acuity (VA) of 1.14 lines (P<0.01) was observed comparing last visit VA with baseline VA. During the follow–up period, patients required a mean of 1.25 treatments (159 patients 1 treatment, 32 patients 2 treatments, 6 patients 3 treatments, 2 patients 4 treatments) to achieve persistent inactivation of the neovascular membrane. A transient increase in intraocular pressure was observed in 38 patients(19.1%) and was controlled by antiglaucomatous topical medication. Thirteen patients(6.5%) with preexisting glaucoma continued their usual topical medication. One patient required surgery for persistent increased IOP. Conclusions: Intravitreal administration of triamcinolone in combination with verteporfin therapy improved mean VA in patients in this case series. The treatment was well tolerated with transient and controllable increase in IOP.

Keywords: age-related macular degeneration • photodynamic therapy • choroid: neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.